Advertisement

Topics

Clinical Trials About "Nisoldipine" RSS

06:26 EST 25th November 2017 | BioPortfolio

We list hundreds of Clinical Trials about "Nisoldipine" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Nisoldipine" on BioPortfolio

We have published hundreds of Nisoldipine news stories on BioPortfolio along with dozens of Nisoldipine Clinical Trials and PubMed Articles about Nisoldipine for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nisoldipine Companies in our database. You can also find out about relevant Nisoldipine Drugs and Medications on this site too.

Showing "Nisoldipine" Clinical Trials, all 3

Relevant

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months


Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 30 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 30 mg tablet (manufactured for First Horizon) following a single, oral 30 mg (1 × 30 mg tablet) dose administration in healthy adult subjects under fasting conditions.

Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fed conditions.



More From BioPortfolio on "Nisoldipine"

Quick Search
Advertisement